Abstract
Due to the emergence of Staphylococcus aureus with reduced vancomycin susceptibility, newer antibiotics, including daptomycin, have been used to treat methicillin-resistant S aureus infections. Daptomycin is a cyclic lipopeptide that is approved to treat S aureus bacteremia and right-sided endocarditis, and reports of S aureus with reduced susceptibility to daptomycin are infrequent. To our knowledge, the present report describes the first Canadian case of daptomycin-nonsusceptible, vancomycin-intermediate S aureus infection.
Highlights
Due to the emergence of Staphylococcus aureus with reduced vancomycin susceptibility, newer antibiotics, including daptomycin, have been used to treat methicillin-resistant S aureus infections
Due to the persistence of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia, the antibiotic was changed to daptomycin (6 mg/kg every 48 h) on day 8 after the repeat positive blood culture results
The MRSA isolate from this episode showed a vancomycin minimum inhibitory concentration (MIC) of 4 mg/L and a daptomycin MIC >4 mg/L by Etest and Sensititre (TREK Diagnostics Inc, USA)
Summary
Due to the emergence of Staphylococcus aureus with reduced vancomycin susceptibility, newer antibiotics, including daptomycin, have been used to treat methicillin-resistant S aureus infections. Due to the persistence of MRSA bacteremia, the antibiotic was changed to daptomycin (6 mg/kg every 48 h) on day 8 after the repeat positive blood culture results.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
